Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00118235 · ClinicalTrials.gov registry record · Phase 2

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
2
Study locations

NCT00118235: Completed Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by National Cancer Institute (NCI).

NCT00118235 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 173-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00118235, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. Giving cisplatin and irinotecan together with bevacizumab may kill more tumor cells.

Primary Outcome

Described using Kaplan-Meier curves.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG cisplatin
  • BIOLOGICAL bevacizumab
  • DRUG irinotecan hydrochloride

Study Locations (2)

Illinois

  • Cancer and Leukemia Group B - Chicago

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2004-12
Est. Completion 2011-07
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00118235 record still lists

NCT00118235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 173-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (58% lower).

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00118235 reports a single indexed study location in Illinois, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00118235 about?

NCT00118235 is a clinical study titled "Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer". This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by...

What is the current status of trial NCT00118235?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2004-12. Estimated completion is 2011-07.

What conditions does trial NCT00118235 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT00118235?

The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), bevacizumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00118235?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00118235 being conducted?

This trial has 2 study locations across Illinois, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00118235's enrollment target sits among peer trials

72 16th of 25 higher than 10 of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00118235, the US trial registry maintained by the National Library of Medicine. NCT00118235 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.